1] Siegel R. Naishadham D, Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2011. Available at: http://dx.doi.org/10.3322/caac.20138.Accessed September 24, 2012.
2] Dobrescu et al. Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer. ISRN Oncology.Vol. 2011, Article ID673790.http://www.isrn.com/journals/oncology/2011/673790/. Accessed September 24, 2012.
4] FARESTON [package insert]. Memphis, TN: GTx, Inc. 2004.
5] Data on file, GTx, Inc.
6] Hayes DF, Van Syl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J ClinOncol. 1995;13:2556-2566.
7] Gershanovich M, Garin A, Baltina D, et al. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer.Breast Cancer Res Treat. 1997;45:251-262.
8] Pyrthonen S, Valavaara R, Modig H, et al. Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. Br J Cancer. 1997;76:270-277.
10] ABSTRAL [package insert]. Bedminister, NJ: ProStrakan, Inc. 2008.
Notes to Editors About ProStrakan
ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets.
ProStrakan is a subsidiary of Kyowa Hakko Kirin Co. Ltd., the Japan-based global specialty pharmaceutical company.
ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels and Bridgewater, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.